{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:08:00Z","timestamp":1770509280078,"version":"3.49.0"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T00:00:00Z","timestamp":1366588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0061416","type":"journal-article","created":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T03:07:18Z","timestamp":1366686438000},"page":"e61416","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":60,"title":["Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis"],"prefix":"10.1371","volume":"8","author":[{"given":"Thanyanan","family":"Chaowanachan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Krogstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Woodrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ni.2264","article-title":"Lessons learned from HIV-1 vaccine trials: new priorities and directions","volume":"13","author":"AJ McMichael","year":"2012","journal-title":"Nature Immunology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri2302","article-title":"Setting the stage: host invasion by HIV","volume":"8","author":"F Hladik","year":"2008","journal-title":"Nature Reviews Immunology"},{"key":"ref3","unstructured":"Joint United Nations Programme on HIV\/AIDS and World Health Organization (2009) AIDS epidemic update. Geneva: UNAIDS. 21\u201322."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.1112489","article-title":"HIV\/AIDS in women: An expanding epidemic","volume":"308","author":"TC Quinn","year":"2005","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.1161000","article-title":"Perspective - HIV vaccine research: The way forward","volume":"321","author":"AS Fauci","year":"2008","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(11)60878-7","article-title":"Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women","volume":"378","author":"SSA Karim","year":"2011","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/wnan.118","article-title":"Nanotechnology and HIV: potential applications for treatment and prevention","volume":"2","author":"PS Kim","year":"2010","journal-title":"Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.antiviral.2010.09.006","article-title":"Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines","volume":"88","author":"KJ Whaley","year":"2010","journal-title":"Antiviral Research"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jama.283.3.381","article-title":"Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel","volume":"283","author":"CCJ Carpenter","year":"2000","journal-title":"Jama-Journal of the American Medical Association"},{"key":"ref10","first-page":"1816","article-title":"Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery (vol 108, pg 2827, 2006)","volume":"109","year":"2007","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2006-03-012534","article-title":"Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery","volume":"108","author":"H Dou","year":"2006","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s11481-010-9198-7","article-title":"Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics","volume":"5","author":"AS Nowacek","year":"2010","journal-title":"Journal of Neuroimmune Pharmacology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/nnm.09.71","article-title":"NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery","volume":"4","author":"AS Nowacek","year":"2009","journal-title":"Nanomedicine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.00976-10","article-title":"Combinatorial Approaches to the Prevention and Treatment of HIV-1 Infection","volume":"55","author":"V Pirrone","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref15","first-page":"533","article-title":"Progress in antiretroviral drug delivery using nanotechnology","volume":"5","author":"R Mallipeddi","year":"2010","journal-title":"International Journal of Nanomedicine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.addr.2009.11.017","article-title":"Nanotechnology-based systems for the treatment and prevention of HIV\/AIDS","volume":"62","author":"J das Neves","year":"2010","journal-title":"Advanced Drug Delivery Reviews"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.addr.2009.11.020","article-title":"Nanotechnology applications for improved delivery of antiretroviral drugs to the brain","volume":"62","author":"HL Wong","year":"2010","journal-title":"Advanced Drug Delivery Reviews"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","article-title":"Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages","volume":"150","author":"AS Nowacek","year":"2011","journal-title":"Journal of Controlled Release"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1124\/mol.59.4.806","article-title":"P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir","volume":"59","author":"MT Huisman","year":"2001","journal-title":"Molecular Pharmacology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1089\/aid.2006.0310","article-title":"Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz","volume":"23","author":"K Borroto-Esoda","year":"2007","journal-title":"Aids Research and Human Retroviruses"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1128\/AAC.00733-08","article-title":"Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro Modulation of ABC Transporter and Intracellular Drug Accumulation","volume":"53","author":"L Bousquet","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":"HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter","volume":"37","author":"CGL Lee","year":"1998","journal-title":"Biochemistry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.aids.0000210608.70762.c3","article-title":"Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women","volume":"20","author":"KH Mayer","year":"2006","journal-title":"AIDS"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1371\/journal.pmed.0050157","article-title":"Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel","volume":"5","author":"M Cranage","year":"2008","journal-title":"Plos Medicine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/088922201316912772","article-title":"Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance","volume":"17","author":"S Palmer","year":"2001","journal-title":"Aids Research and Human Retroviruses"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1128\/JVI.01073-09","article-title":"Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine","volume":"83","author":"UM Parikh","year":"2009","journal-title":"Journal of Virology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejps.2004.09.011","article-title":"Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles","volume":"24","author":"U Bilati","year":"2005","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/PDT-120017517","article-title":"Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method","volume":"8","author":"U Bilati","year":"2003","journal-title":"Pharmaceutical Development and Technology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1023\/B:PHAM.0000036917.75634.be","article-title":"Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods","volume":"21","author":"S Galindo-Rodriguez","year":"2004","journal-title":"Pharmaceutical Research"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/bmc.631","article-title":"HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice","volume":"20","author":"K Mudigonda","year":"2006","journal-title":"Biomedical Chromatography"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","article-title":"A vaginal fluid simulant","volume":"59","author":"DH Owen","year":"1999","journal-title":"Contraception"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"12585","DOI":"10.1128\/JVI.01726-08","article-title":"Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research","volume":"82","author":"Y Takeuchi","year":"2008","journal-title":"Journal of Virology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"CA Derdeyn","year":"2000","journal-title":"Journal of Virology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"EJ Platt","year":"1998","journal-title":"Journal of Virology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"XP Wei","year":"2002","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1128\/JVI.69.6.3712-3720.1995","article-title":"Growth of macrophage-tropic and primary human immodeficiency virus type 1 (HIV-1) isolates in a unique CD4(+) T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1","volume":"69","author":"P Lusso","year":"1995","journal-title":"Journal of Virology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11095-008-9765-2","article-title":"Targeted Delivery of PSC-RANTES for HIV-1 Prevention using Biodegradable Nanoparticles","volume":"26","author":"AS Ham","year":"2009","journal-title":"Pharmaceutical Research"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.01096-08","article-title":"Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides","volume":"53","author":"C Herrera","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/AAC.01129-06","article-title":"Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture","volume":"51","author":"JE Cummins","year":"2007","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref41","article-title":"In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 Microbicide","author":"LC Rohan","year":"2010","journal-title":"PLoS One 5"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1086\/462424","article-title":"A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection","volume":"192","author":"SR Abner","year":"2005","journal-title":"Journal of Infectious Diseases"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkq434","article-title":"Efavirenz concentrations in CSF exceed IC50 for wild-type HIV","volume":"66","author":"BM Best","year":"2011","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/cr60274a001","article-title":"Partition coefficients and their uses","volume":"71","author":"A Leo","year":"1971","journal-title":"Chemical Reviews"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system","volume":"58","author":"M Lindenberg","year":"2004","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"ref46","first-page":"4187","article-title":"Zeta Potential of Colloids in Water and Waste Water","year":"1985","journal-title":"ASTM Standard D"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nmat2444","article-title":"Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA","volume":"8","author":"KA Woodrow","year":"2009","journal-title":"Nature Materials"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/S0142-9612(00)00115-0","article-title":"The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices","volume":"21","author":"RA Jain","year":"2000","journal-title":"Biomaterials"},{"key":"ref49","article-title":"Combination antiretroviral drugs in PLGA nanoparticle for HIV-1","author":"CJ Destache","year":"2009","journal-title":"Bmc Infectious Diseases 9"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2011.08.032","article-title":"A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles","volume":"157","author":"O Mert","year":"2012","journal-title":"Journal of Controlled Release"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1016\/j.biomaterials.2011.05.008","article-title":"Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus","volume":"32","author":"SK Lai","year":"2011","journal-title":"Biomaterials"},{"key":"ref52","article-title":"The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study","author":"JY Feng","year":"2009","journal-title":"Retrovirology 6"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1023\/A:1022219003551","article-title":"Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells","volume":"20","author":"J Panyam","year":"2003","journal-title":"Pharmaceutical Research"},{"key":"ref54","article-title":"Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery","author":"J Panyam","year":"2002","journal-title":"Faseb Journal 16"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkq318","article-title":"Antiretroviral release from poly(dl-lactide-co-glycolide) nanoparticles in mice","volume":"65","author":"CJ Destache","year":"2010","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"WR Greco","year":"1995","journal-title":"Pharmacological Reviews"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/clinchem\/46.1.73","article-title":"Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma","volume":"46","author":"RP Remmel","year":"2000","journal-title":"Clinical Chemistry"},{"key":"ref58","first-page":"93","article-title":"Saquinavir - A review of its pharmacology and clinical potential in the management of HIV infection","volume":"52","author":"S Noble","year":"1996","journal-title":"Drugs"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.pharmtox.40.1.649","article-title":"Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits","volume":"40","author":"C Flexner","year":"2000","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.colsurfb.2011.07.053","article-title":"Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field","volume":"88","author":"YC Kuo","year":"2011","journal-title":"Colloids and Surfaces B-Biointerfaces"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s11095-006-9101-7","article-title":"Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV\/AIDS","volume":"23","author":"LK Shah","year":"2006","journal-title":"Pharmaceutical Research"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1023\/B:PHAM.0000045225.76650.53","article-title":"Miniature device for aqueous and non-aqueous solubility measurements during drug discovery","volume":"21","author":"XQ Chen","year":"2004","journal-title":"Pharmaceutical Research"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s11095-011-0622-3","article-title":"Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine","volume":"29","author":"J das Neves","year":"2012","journal-title":"Pharmaceutical Research"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"BL Jilek","year":"2012","journal-title":"Nature Medicine"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0061416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:12:38Z","timestamp":1745993558000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0061416"}},"subtitle":[],"editor":[{"given":"Shibo","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,22]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0061416","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,22]]}}}